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Summary
 
The 
 
galU
 
 gene of 
 
Streptococcus pneumoniae
 
 has been cloned and sequenced. 
 
Escherichia coli
 
 cells
harboring the recombinant plasmid pMMG2 (
 
galU
 
) overproduced a protein that has been
shown to correspond to a uridine 5
 
9
 
-triphosphate:glucose-1-phosphate uridylyltransferase
(uridine diphosphoglucose [UDP-Glc] pyrophosphorylase) responsible for the synthesis of
UDP-Glc, a key compound in the biosynthesis of polysaccharides. A gene very similar to the
 
S. pneumoniae galU
 
 has been found in a partial nucleotide sequence of the 
 
Streptococcus pyogenes
 
genome. Knockout 
 
galU
 
 mutants of type 1 pneumococci are unable to synthesize a detectable
capsule. An identical result was found in type 3 
 
S. pneumoniae
 
 cells in spite of the fact that these
bacteria contain a type-specific gene (
 
cap3C
 
) that also encodes a UDP-Glc pyrophosphorylase.
Since eukaryotic UDP-Glc pyrophosphorylases appear to be completely unrelated to their
prokaryotic counterparts, we postulate that GalU may be an appropriate target for the search of
new drugs to control the pathogenicity of bacteria like pneumococcus and 
 
S. pyogenes.
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S
 
treptococcus pneumoniae
 
 (pneumococcus) remains a major
cause of morbidity and mortality throughout the world
and its continuous increase in antimicrobial resistance is
rapidly becoming a leading cause of concern for public
health. Pneumococcal infection persists as the main caus-
ative agent of pneumonia, meningitis, and otitis media.
These diseases remain as the most prevalent infections in
many areas of the world, particularly in infants, the elderly,
and in immunocompromised patients. As shown in a re-
cent study (1), although a 68% reduction in total invasive
diseases due to 
 
Haemophilus influenzae
 
 type b was observed
in the United States after licensure of the conjugated vac-
cine, a concomitant increase of 74% in the number of cases
per 100,000 population for invasive pneumococcal diseases
was also found. Although 
 
S. pneumoniae
 
 produces several
virulence factors (for review see reference 2), as early as
1928 Griffith reported that unencapsulated pneumococcal
variants were avirulent (3), and that loss of the capsule is
accompanied by a 10
 
5
 
-fold reduction of the virulence of 
 
S.
pneumoniae.
 
 Unencapsulated pneumococci are readily phago-
cytized when added to a suspension of leukocytes in nor-
mal serum, whereas mucoid, capsulated organisms are resis-
tant to phagocytosis and multiply rapidly. A quantitative
relationship between the amount of type-specific poly-
saccharide and virulence has been found (4, 5), although
the chemical composition of the capsule (6) as well as the
cellular background in which the capsule is produced also
appear to play an important role in virulence (7).
90 different pneumococcal types have been described
(8). This remarkable phenotypic variability appears to be
present also at the genetic level (9–11), which has pre-
cluded until now the search for drugs capable of inhibiting
the synthesis of the capsular polysaccharides of 
 
S. pneumo-
niae.
 
 The chemical structure of the repeat unit of these
polysaccharides is known in more than half of the types
described, most of them contain glucose (Glc)
 
1
 
 and/or ga-
lactose (Gal) or various derivatives of them in addition to
other sugars (12). Early studies carried out by Mills and
co-workers (for review see reference 13) showed that uri-
dine diphosphoglucose (UDP-Glc) is a key component in
 
1
 
Abbreviations used in this paper:
 
 Gal, galactose; GAS, group A streptococci;
Glc, glucose; Ln, lincomycin; UDP-GalA, uridine diphosphogalacturonic
acid; UDP-Glc, uridine diphosphoglucose; UDP-GlcA, uridine diphos-
phoglucuronic acid; UDPG:PP, uridine diphosphoglucose pyrophos-
phorylase.
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the biosynthetic pathway of pneumococcal capsular poly-
saccharides containing Glc, Gal, and/or UDP-glucuronic
(UDP-GlcA) or UDP-galacturonic (UDP-GalA) acids (Fig.
1). The enzyme UTP:glucose-1-phosphate uridylyltransferase
(UDP-Glc pyrophosphorylase, UDPG:PP) (EC 2.7.7.9)
catalyzes the formation of UDP-Glc, which is the substrate
for the synthesis of UDP-GlcA. UDP-Glc is also required
for the interconversion of Gal and Glc by way of the Leloir
pathway (14), and consequently, mutants of 
 
Escherichia coli
 
deficient in UDPG:PP activity cannot ferment Gal and fail
to incorporate Glc and Gal into bacterial cell membranes,
resulting in the incomplete synthesis of lipopolysaccharide
(15). The gene 
 
cap3C
 
 of 
 
S. pneumoniae
 
, one of the three
genes located in the type 3–specific capsular operon, encodes
a UDPG:PP that has been shown to be dispensable for cap-
sule production (16, 17). This result strongly suggests that
another different gene might also encode a UDPG:PP that,
in addition, might be common to all of the pneumococci. In
favor of this assumption is the fact that, apart from 
 
cap3C
 
, a
gene putatively encoding a UDPG:PP has not been found in
any of the capsular clusters studied so far (9–11).
A partial (and still preliminary) nucleotide sequence of
the genome of a type 4 pneumococcus has been released
recently (ftp://ftp.tigr.org/pub/data/s_pneumoniae). This
has allowed the search for genes coding for proteins similar
to the Cap3C pyrophosphorylase and we report here the
cloning, expression, and characterization of the 
 
galU
 
 gene
of 
 
S. pneumoniae.
 
 We show that the pneumococcal 
 
galU
 
mutants of types 1 and 3 did not synthesize detectable
amounts of capsular polysaccharide.
 
Materials and Methods
 
Bacterial Strains, Plasmids, and Growth Conditions.
 
The bacte-
rial strains and the plasmids used in this study are shown in Table
1. Unless otherwise stated, 
 
S. pneumoniae
 
 was grown in liquid C
medium (18) containing 0.08% yeast extract (C 
 
1
 
 Y) without
shaking or on reconstituted tryptose blood agar base plates (Difco
Laboratories Inc., Detroit, MI) supplemented with 5% defibri-
nated sheep blood. 
 
E. coli
 
 cells were grown in Luria-Bertani me-
dium (19). When required, ampicillin was added to the medium
at 100 
 
m
 
g/ml. Chromosomal DNA and plasmid purification, and
transformation of 
 
E. coli
 
 and laboratory strains of 
 
S. pneumoniae
 
were carried out as described elsewhere (20). 
 
S. pneumoniae
 
 clones
obtained upon transformation with pUCEK2 or pMMG1 (Table
1) were scored on blood agar plates containing 0.7 
 
m
 
g of linco-
mycin (Ln) per ml. MacConkey agar plates (Difco Laboratories,
Inc.) containing 0.6% galactose were used for 
 
E. coli
 
 fermentation
tests.
 
DNA Techniques and Plasmid Construction.
 
Restriction endo-
nucleases, T4 DNA ligase, and the Klenow (large) fragment of
DNA polymerase I were obtained commercially and used accord-
ing to the recommendations of the suppliers. Gel electrophoresis
of plasmids, restriction fragments, and PCR products was carried
out in agarose gels as described (19). DNA was recovered from
gel slices with the Gene Clean Kit (Bio 101, La Jolla, CA).
 
S. pneumoniae
 
 DNA digested with either SmaI, SacII, or ApaI
was analyzed by pulsed-field gel electrophoresis (PFGE) using a
contour-clamped homogeneous electric field DRII apparatus
(Bio–Rad, Hercules, CA) as previously described (21).
PCR amplifications were performed using 2 U of 
 
AmpliTaq
 
TM
 
DNA polymerase (Perkin-Elmer Applied Biosystems, Norwalk,
CT), 1 
 
m
 
g of chromosomal (or plasmid) DNA, 1 
 
m
 
M of each syn-
thetic oligonucleotide primer, 200 
 
m
 
M of each deoxynucleoside
triphosphate, and 2.5 mM of MgCl
 
2
 
 in the buffer recommended by
the manufacturer. Conditions for amplification were chosen accord-
ing to the G 
 
1
 
 C content of the corresponding oligonucleotide.
The oligonucleotides used were: (624), 5
 
9
 
-TTGGTAccTGAAA-
CAACTGGCATGC-3
 
9
 
 (primer OGalU1); (1139/c) 5
 
9
 
-CCCAA-
CGTCGTAACGAGcTCCTG-3
 
9
 
 (primer OGalU2); (1464/c),
5
 
9
 
-GAGCAaTTGGTGGCGCATTTCTAGC-3
 
9
 
 (primer OGalU3);
(323), 5
 
9
 
-TGAGTcGaCTTAACCCTCTATAGAAAG-3
 
9
 
 (primer
OGalU4); (659/c), 5
 
9
 
-GAAATGAAGGCGCATGCCAGTTG-3
 
9
 
(primer IGalU1); (773), 5
 
9
 
-CGAGAAGGCCGTTCCTTTGAC-3
 
9
 
(primer IGalU2). Numbers indicate the position of the first nucleo-
tide of the primer in the sequence reported in this paper (see be-
low), and /c means that the corresponding sequence corresponds
to the complementary strand. Lowercase letters indicate nucle-
otides introduced to construct appropriate restriction sites. These
are shown underlined. For inverse PCR, DNA prepared from
strain 406 was digested with ClaI, and the resulting fragments
were diluted 10-fold and self-ligated. Afterwards, the DNA was
concentrated by ethanol precipitation and amplified by PCR using
oligonucleotides IGalU1 and IGalU2.
To construct pMMG2 (Table 1), DNA prepared from the type
3 strain 406 was amplified with oligonucleotides OGalU3 and
OGalU4 and the 1.1-kb DNA fragment was purified, digested
with MunI and SalI, and ligated to EcoRI/SalI-digested pUC19.
Plasmid pMMG1, which contains a 0.5-kb internal fragment of
the gene 
 
galU
 
 (Table 1), was constructed as follows: DNA pre-
pared from strain 406 was amplified with primers OGalU1 and
OGalU2 and the 0.5-kb DNA fragment was purified, digested
with KpnI and ClaI, and ligated to pUCE191 previously digested
with KpnI plus AccI.
NEBlot
 
TM
 
 Phototope
 
TM
 
 Kit (Millipore Corp., Bedford, MA)
was used to construct biotin-labeled probes and Phototope
 
TM
 
 6K
Detection Kit (Millipore Corp.) for the chemiluminescent detec-
tion. Southern blots, dot blots, and hybridizations were carried
out according to the manufacturer’s instructions. Figure 1. Metabolic pathway of UDP-Glc. 
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Nucleotide Sequence and Data Analysis.
 
DNA sequencing was
carried out by using an Abi Prism 377
 
TM
 
 DNA sequencer (Ap-
plied Biosystems Inc., Foster City, CA). DNA and protein se-
quences were analyzed with the Genetics Computer Group soft-
ware package (version 9.0) (22). Sequence similarity searches
were done by using the EMBL/GenBank, SWISS-PROT, and
PIR databases.
 
SDS-PAGE and NH
 
2
 
-terminal Amino Acid Sequence Analysis.
 
SDS-PAGE was carried out as described by Laemmli using 10%
gels (23). After SDS-PAGE, proteins were blotted onto a polyvi-
nylidene difluoride membrane (Immobilon-P
 
SQ
 
, Millipore Corp.),
and stained briefly with Amido black (Sigma Chemical Co., St.
Louis, MO). Subsequently, the desired band was cut and the
NH
 
2
 
-terminal amino acid sequence was determined as described
elsewhere (24).
 
Miscellaneous Techniques.
 
The test for carbohydrate fermenta-
tion by pneumococcal strains was carried out in Heart infusion
broth (Difco Laboratories, Inc.) with the appropriate carbohy-
drate added at 1% (final concentration) as previously described
(25). For immunoagglutination assays (26), 
 
S. pneumoniae
 
 cells
were incubated on C medium containing 0.1% BSA and different
amounts of anti-R antiserum. Anti-R (antisomatic) antiserum
contains group-specific agglutinins that, at a convenient dilution,
agglutinate only rough pneumococci, and was raised in rabbits as
 
Table 1.
 
Bacterial Strains and Plasmids
 
Strain or 
plasmid Relevant genotype or phenotype Source or reference
 
S. pneumoniae
 
13868 S1
 
1
 
 LytA
 
1
 
20
9060 S1
 
1
 
 LytA
 
1
 
20
14388 S1
 
1
 
 LytA
 
1
 
20
M25 S1
 
1
 
 
 
lytA
 
20
M25 g
 
*
 
galU
 
::pUCE191 
 
lytA
 
This study
406 S3
 
1
 
 LytA
 
1
 
45
M23 S3
 
1
 
 
 
lytA
 
45
M23 c
 
‡
 
cap3C
 
::pUCE191 
 
lytA
 
16
M23 g
 
§
 
galU
 
::pUCE191 
 
lytA
 
This study
M24
 
cap3A
 
 (S3
 
2
 
) 
 
lytA
 
45
M24 g
 
i
 
galU
 
::pUCE191 
 
lyt
 
A This study
335/95 S51 LytA1 A. Fenoll
6028/95 S81 LytA1 A. Fenoll
536/96 S91 LytA1 A. Fenoll
13783/90 S141 LytA1 A. Fenoll
17A S17A1 LytA1 Statens Seruminstitut
8249 S19A1 LytA1 46
436/96 S311 LytA1 A. Fenoll
SSISP 33A/1 S33A1 LytA1 Statens Seruminstitut
1235/89 S371 LytA1 A. Fenoll
E. coli strains
DH5a (f80lacZDM15) endA1 recA1 hsdR17 (rk
2mk
2) supE44 DlacU169 thi-1 leuB thr-1 47
TG1 supE hsdD5 thi D(lac-proAB) F9 (traD36 proAB1 lacIq lacZDM15) 19
FF4001 MC4100 galU95 48
Plasmids
pUC19 Cloning vector (ApR)4 9
pUCE191 Cloning vector (ApR, LnR)1 6
pUCEK2 Internal fragment of cap3C cloned into pUCE191 16
pMMG1 0.45-kb internal fragment of S. pneumoniae galU cloned into pUCE191 This study
pMMG2 galU gene from S. pneumoniae strain 406 cloned into pUC19 This study
*Strain constructed by transformation of M25 with DNA from strain M24 g.
‡Strain constructed by transformation of M23 with pUCEK2.
§Strain constructed by transformation of M23 with DNA from M24 g.
iStrain constructed by transformation of M24 with pMMG1.2050 Pneumococcal UDP-Glucose Pyrophosphorylase and Capsular Biosynthesis
previously described (26). Purification of capsular polysaccharides
and double-diffusion experiments were performed as described
previously (27). To estimate the amount of polysaccharide
present in a sample, 5 ml of serial dilutions of the extract and
known amounts of purified polysaccharide were analyzed by im-
munodiffusion against 5 ml of the same batch of antiserum.
Nucleotide Sequence Accession Number. The DNA sequence de-
scribed here is deposited with the EMBL database under accession
No. AJ004869.
Results
Identification, Cloning, Sequencing, and Mapping of a Pneu-
mococcal Gene Similar to cap3C. The deduced amino acid
sequence of the cap3C gene was compared to the translated
version of the nucleotide sequence of a type 4 pneumococ-
cal strain that has been released recently. A gene (hereafter
designated galU) encoding a protein 77% identical to Cap3C
was located in the 12,128-bp contig No. 4225. Analysis of
this gene and its surrounding regions (Fig. 2) revealed that
contig No. 4225 does not contain the type 4–specific cap-
sular cluster which appears to be localized in the contig
No. 4108 (34,280 bp). The putative galU gene is preceded
by a gene whose product showed strong similarity to the
GpsA NAD(P)H-dependent dihydroxyacetone-phosphate
reductase of Bacillus subtilis (28) (Table 2). The galU and the
gpsA genes are only 21 bp apart. Other genes surrounding
gpsA-galU were preliminarily identified on the basis of se-
quence similarities with the exception of orf5 and orf6,
which did not show any significant similarities to those
available in the data banks.
Preliminary efforts to amplify by PCR the galU gene us-
ing DNA prepared from the S. pneumoniae type 3 strain 406
were unsuccessful when using oligonucleotide primers de-
signed from the nucleotide sequence of genes gpsA and orf5
from type 4 pneumococci. However, successful amplifica-
tion was achieved with OGalU3 and OGalU4, which cor-
respond to the 59 end of orf6 and to the 39 end of gpsA, re-
spectively. The 1.1-kb PCR fragment was cloned into
pUC19 to create pMMG2 (Table 1). Moreover, inverse
PCR using oligonucleotides IGalU1 and IGalU2 (designed
from the nucleotide sequence of the SalI-MunI insert of
pMMG2) produced a 2.3-kb DNA fragment that was par-
tially sequenced. Determination of the sequence of 1,464
bp revealed that the orf5 gene was not present in 406 DNA,
which accounts for the amplification failures discussed
above. It should be noted that the nucleotide sequence of
the galU406 gene (900 bp) was nearly identical (89%) to that
of the type 4 isolate (not shown).
The absence of orf5 in strain 406 prompted us to analyze
whether other important differences exist among various
pneumococcal isolates. Southern blot analysis of HindIII-
digested chromosomal DNA prepared from a variety of
pneumococcal strains using a 0.7-kb SalI-ClaI fragment of
pMMG2 showed that all the strains tested contain at least
one copy of the galU gene (Fig. 3). In the case of strains
6028/95 (S81) and SSIP 33A/1 (S33A1), the pattern of hy-
bridization might suggest the existence of a second copy of
galU in their DNAs, although we favor the hypothesis that
the 5.5-kb DNA band was incompletely cleaved in those
two strains. Nevertheless, this point was not further investi-
gated.
Fig. 4 shows a multiple alignment of the amino acid se-
quence of the galU406 gene product with the proteins avail-
able in the databases. HasC, a UDPG:PP from the has op-
eron required for expression of the hyaluronic acid capsule
of Streptococcus pyogenes (29), showed the highest similarity
to the pneumococcal GalU (.85% identical amino acids
and 90.9% similarity). About 87% sequence similarity (77%
identity) was found between the pneumococcal GalU and
Cap3C proteins. Although not yet included in the data
banks, a search of a partial nucleotide sequence of the S.
pyogenes genome (http://www.genome.ou.edu/strep.html)
for genes similar to galU (and hasC) showed that, as in S.
pneumoniae, group A streptococci (GAS) also contain a galU
homologue located in the contig No. 234 (8061 bp) (Fig.
2). The similarity between the GalU proteins of S. pneumo-
niae and S. pyogenes was even higher than that found be-
tween the former and the type 3–specific Cap3C UDPG:PP
of S. pneumoniae (Fig. 4). Lower but significant similarities
were also found between the pneumococcal GalU and
UDPG:PPs from B. subtilis (30) and E. coli (31) as well as
with the GalF protein of E. coli that modulates the activity
of the GalU enzyme (32).
To determine the location of galU in the pneumococcal
genome, chromosomal DNA of strain M24, a descendant
of the classical laboratory strain R6 (33), was digested with
SmaI, ApaI, or SacII, subjected to PFGE, blotted, and hy-
bridized with the 0.7-kb SalI-ClaI fragment of pMMG2
(see above). The results shown in Fig. 5 indicated that the
galU gene resides in fragments 5 (SmaI, 235 kb), 4 (ApaI,
235 kb), and 13 (SacII, 54 kb) of the physical map of the
pneumococcal genome (34).
Overproduction and Characterization of the S. pneumoniae
GalU Protein. E.  coli DH5a cells harboring pMMG2
were incubated overnight at 378C with shaking in LB me-
Figure 2. Genetic organization of two S. pneumoniae strain (types 3 and
4) DNAs containing the galU gene. The corresponding region of the S.
pyogenes DNA is also shown. Thick and thin arrows represent complete or
interrupted orfs, respectively. Identical shading represents DNA regions
coding for the same putative protein. Relevant restriction sites are indi-
cated (C, ClaI; K, KpnI; M, MunI; Sa, SalI). An asterisk indicates that the
corresponding restriction site has been introduced using a synthetic oligo-
nucleotide. Filled key represents a putative transcription terminator.2051 Mollerach et al.
dium containing ampicillin (100 mg/ml). Crude extracts
obtained by sonication were analyzed by 10% SDS-PAGE
and a prominent protein band of z37 kD was observed
(Fig. 6, lane 2). This band was absent in crude extract pre-
pared from E. coli DH5a cells containing the vector plas-
mid pUC19 (Fig. 6, lane 3). The molecular mass of the 37-
kD overproduced protein was in fair agreement with that
deduced from the nucleotide sequence of the galU gene
(33,213 D). It should be mentioned that an apparent
38,000  Mr has been reported for the purified E. coli GalU
whereas a molecular mass of 32,291 D was predicted from
the sequence of the galU gene (31). The NH2-terminal
amino acid sequence of the protein was determined, yield-
ing Met-Thr-Ser-Lys-Val-Arg-Lys-Ala-Val-Ile, which con-
firmed the sequence deduced from the nucleotide sequence
of the gene (Fig. 4).
To ascertain that the pneumococcal galU gene codes for
a UDPG:PP, the pGMM2 plasmid was introduced by
transformation into the galU E. coli mutant strain FF4001.
This mutant contains a T to C mutation causing the substi-
tution of a proline residue by a serine one in the predicted
amino acid sequence of the GalU protein and virtually
lacks UDPG:PP activity (31). Ampicillin-resistant transfor-
mants scored on MacConkey-galactose plates grew as red
colonies indicating that they were able to ferment the sugar
(not shown). This result confirmed that the galU gene of S.
pneumoniae encodes a UDPG:PP.
Construction and Characterization of galU Mutants of Pneu-
mococcus. To construct galU mutants of S. pneumoniae
lacking UDPG:PP, insertion-duplication mutagenesis was
carried out using plasmid pMMG1 that contains an internal
fragment of the galU gene cloned into pUCE191 (Table 1).
Table 2. The galU Genes of S. pneumoniae and S. pyogenes and Their Surrounding orfs: Properties and Similarities in the Database
Protein
Predicted
protein
(aa/kD)
Proposed
function
Most similar
polypeptide
Database
accession
No.
Degree of identity/
similarity (%) Organism
S. pneumoniae DNA (contig no. 4225, partial)
Orf1* 78/8.2 Phosphate transporter permease Mth1730 AE000929 40.5/68.9 Methanobacterium 
thermoautotrophicum
Orf2 250/28.1 Phosphate transport system
ATP-binding protein Mj1012 U67544 66.8/83.2 Methanococcus jannaschii
Orf3 216/24.2 Negative regulator PhoU D89963 30.7/53.2 Enterobacter cloacae
Orf4‡ 159/18.5 Transposase Transposase X84038 25.0/49.3 Xanthobacter autotrophycus
GpsA 338/36.8 NAD(P)H-dependent
dihydroxyacetone-phosphate
reductase GpsA U32164 53.0/70.7 B. subtilis
GalU 299/33.2 UDP-Glc pyrophosphorylase HasC U33452 85.2/90.9 S. pyogenes
Orf5 313/34.7 Unknown
Orf6 225/25.0 Unknown Orf2 Z46863 30.4/59.9 Acinetobacter calcoaceticus
Orf7 179/20.6 5-Formyltetrahydrofolate
cyclo-ligase YqgN Z99116 39.7/63.7 B. subtilis
Orf8 376/41.7 Amino acid hydrolase YkuR AJ222587 46.2/63.7 B. subtilis
Orf9* 232/23.9 Acetyltransferase YkuQ AJ222587 59.0/71.2 B. subtilis
S. pyogenes DNA (contig no. 234)
Orf1 255/29.7 Unknown HI0882 U32770 33.8/51.3 H. influenzae
Orf2 594/66.8 ABC transporter YfiC Z99108 36.5/60.0 B. subtilis
Orf3 568/63.0 ABC transporter YfiB Z99108 33.9/59.5 B. subtilis
Orf4 149/17.3 Transcriptional regulator YybA Z99124 20.8/48.6 B. subtilis
GspA 338/36.7 NAD(P)H-dependent
dihydroxyacetone-
phosphate reductase GpsA U32164 53.0/71.3 B. subtilis
GalU 299/33.3 UDP-Glc pyrophosphorylase HasC U33452 90.3/94.3 S. pyogenes
Orf5* 212/23.2 Unknown YqgB Z99116 24.1/44.9 B. subtilis
aa, amino acids.
*Partial ORF.
‡Interrupted reading frame.2052 Pneumococcal UDP-Glucose Pyrophosphorylase and Capsular Biosynthesis
A Ln-resistant transformant (designated as M24 g) was iso-
lated upon transformation of the pneumococcal strain M24
with pMMG1 isolated from E. coli TG1. Carbohydrate-
fermentation tests showed that M24 g fermented Glc but
was unable to use Gal as a carbon source (not shown).
Chromosomal DNA prepared from strain M24 g was
used to transform the encapsulated strains M23 (S31) and
M25 (S11) and Ln-resistant clones were picked for further
study. As found for M24 g, the transformant strains M23 g
and M25 g were also unable to ferment Gal whereas M23 c
did ferment either Glc or Gal. Furthermore, when the
M23  g strain was grown in blood agar plates, small, rough-
like colonies were formed, in sharp contrast with the big,
smooth colonies typical of type 3 strains of S. pneumoniae
(Fig. 7). As reported before (16), no major differences were
observed between the colonies of M23 and M23 c strains.
Since type 1 pneumococcal strains form small colonies, no
significant differences were found on the morphology of
the colonies of M25 and M25 g (not shown). Encapsulated
pneumococci grow typically in suspension when incubated
in broth, whereas unencapsulated mutants show a tendency
to aggregate at the bottom of the tube. The pneumococcal
galU mutants, but not the cap3C mutants (M24 c), grew as
true unencapsulated strains (Fig. 7) and were agglutinated
with anti-R serum (not shown). Moreover, immunodiffu-
sion analysis of cell extracts using either type 1– or type
3–specific antisera demonstrated that M23 g and M25 g did
not synthesize any detectable capsular polysaccharide (Fig.
7). In contrast, M23 c produced type 3 polysaccharide in
amounts comparable to the M23 strain, which confirmed
previous results (16). To further confirm that GalU is es-
sential for the biosynthesis of capsular polysaccharides in S.
pneumoniae, strains M23 g and M25 g were repeatedly sub-
cultured in Ln-free C medium containing 0.1% BSA and
anti-R antiserum (see Materials and Methods). After several
passages, putatively encapsulated revertants that were not
agglutinated by the serum and thus grew in suspension
were isolated. They appeared to be true galU1 revertants as
judged from the findings that were no longer Ln-resistant
and that the size (1.1 kb) of the PCR fragments obtained
by using oligonucleotide primers OGalU3 and OGalU4
Figure 3. Identification of the galU gene of S. pneumoniae by DNA–
DNA hybridization. Chromosomal DNA from 15 different pneumococ-
cal strains of various types was digested with HindIII, electrophoresed,
blotted, and hybridized with a 0.7-kb SalI-ClaI fragment of pMMG2 (see
Table 1). As size standards, we used a HindIII digest of l DNA.
Figure 4. Computer-generated alignment (PILEUP) of the GalU protein
of S. pneumoniae (Spn GalU) with other similar proteins included in the
databases. The following UDPG:PP were aligned: S. pneumoniae Cap3C
(Spn_Cap3C) (reference 16), S. pyogenes HasC (Spy HasC) (reference 29), B.
subtilis GtaB (Bsu GtaB) (reference 30), and E. coli GalU (Eco GalU) (refer-
ence 31). Other proteins used were GalF of E. coli (Eco GalF) (reference 32)
and the putative UDPG:PP of S. pyogenes, the GalU protein described in
this paper (Spy GalU). The inset shows the percentages of identical/sim-
ilar amino acid residues resulting from pairwise comparisons (BESTFIT).
Figure 5. PFGE of the DNA
prepared from strain M24 of S.
pneumoniae digested with ApaI,
SacI, or SmaI and blotted and
hybridized with the 0.7-kb SalI-
ClaI fragment of pMMG2. The
sizes (in kb) of the SmaI frag-
ments (reference 34) are indi-
cated at the right.2053 Mollerach et al.
and DNA isolated from every revertant tested corre-
sponded to that of the intact galU gene (see above). As ex-
pected, those revertants were able to synthesize a capsular
polysaccharide corresponding to the original, encapsulated
parental strain (type 1 or type 3) as demonstrated immuno-
logically (data not shown).
Discussion
Duplicated genes appear to be rather unusual in bacteria
and consequently type 3 pneumococci and S. pyogenes are
somehow exceptional in having two genes coding for the
same enzyme, namely, a UDPG:PP. The capsular polysac-
charides of both bacteria contain glucuronic acid, and the
genes responsible for their biosynthesis are organized in a
similar fashion (16, 35), i.e., each operon contains three
genes, the gene responsible for the synthesis of UDP-Glc
(cap3C and hasC, in S. pneumoniae and GAS, respectively),
the gene encoding a UDP-Glc dehydrogenase (cap3A and
hasB), and the gene coding for the enzyme responsible for
the synthesis of the type 3 polysaccharide in S. pneumoniae
(cap3B) or hyaluronic acid in S. pyogenes (hasA). As shown
for type 3 pneumococci where cap3C is not required for
capsule formation, only HasA and HasB appear to be re-
quired for hyaluronic acid capsule production both in GAS
and in heterologous bacteria as revealed by Tn916 mu-
tagenesis (36, 37). Furthermore, a gene very similar to the
pneumococcal galU gene described here has been found in
the partial nucleotide sequence of the S. pyogenes genome
that is currently available. It should be mentioned that,
both in S. pneumoniae and S. pyogenes, the galU is immedi-
ately preceded by a gene (gpsA) that is presumably involved
in the synthesis of membrane lipids (28). The significance of
this finding is not currently understood but it is interesting to
point out that gpsA and galU genes are completely unlinked
in other bacteria such as B. subtilis or E. coli.
Figure 6. Expression of the
GalU protein of S. pneumoniae by
E. coli containing the recombi-
nant plasmid pMMG2. E. coli
DH5a cells containing either
pMMG2 or pUC19 vector alone
were incubated overnight on LB
medium, and the crude sonicated
extracts were analyzed by 10%
SDS-PAGE. Lane 2, extracts from
bacteria containing pMMG2.
Lane  3, extracts from bacteria
harboring pUC19. The molecu-
lar masses of the standards (lane
1) are indicated on the left.
Figure 7. Unencapsulated phenotype of the pneumococcal galU mu-
tants. (Top) Colony morphology on blood-agar plates. Bar, 1 mm. (Mid-
dle) Growth characteristics after overnight incubation at 378C in C 1 Y
medium. (Bottom) Double immunodifussion in agarose. The center wells
received type 3 (a) or type 1 (b) antisera. The pneumococcal strains ana-
lyzed were: M23 (A); M23 c (Cap3C) (B); M23 g (GalU) (C); M25 (D);
M25 g (GalU) (E). Purified pneumococcal polysaccharides from type 1
(1) and type 3 (3) were used as positive controls.
Figure 8. Domain arrangement of several UDPG:PP from prokaryotic
and eukaryotic organisms. Bars represent domains and identical shading
indicates high amino acid sequence similarity. The proteins were aligned
according to programs available at the ProDom database (reference 50).
The number assigned to each domain (#) as well as its length in amino
acid residues (aa) are indicated at the top right. The UDPG:PP aligned
correspond to the following species: E. coli (Eco GalU); B. subtilis (Bsu GtaB);
S. pyogenes (Spy HasC and Spy GalU); S. pneumoniae (Spn Cap3C and
Spn GalU); Bos taurus (UDPG Bovin); Homo sapiens (UDPG Human); S.
cerevisiae (UDPG Yeast and UDPH Yeast); Solanum tuberosum (UDPG SolTu);
and Dictyostelium discoideum (UDPG DicDi).2054 Pneumococcal UDP-Glucose Pyrophosphorylase and Capsular Biosynthesis
A relevant role of UDPG:PP for virulence has been rec-
ognized in various gram-negative bacteria (38–40). How-
ever, to the best of our knowledge, there are no data avail-
able in gram-positive organisms concerning the importance
of this protein in pathogenicity. In this work, we have con-
structed galU mutants of two strains of S. pneumoniae of dif-
ferent serotypes, namely types 1 and 3. Both mutants were
unencapsulated according to a series of criteria, i.e., colony
morphology, growth in liquid medium, agglutinability
with anti-R serum, and lack of recognition by type-specific
antiserum. On the other hand, galU1 revertants of strains
M23 g and M25 g synthesized type 1 and type 3 capsules,
respectively. The unencapsulated phenotype of the galU
mutants was expected in the case of the type 1 strain that
apparently does not harbor any other gene encoding a
UDPG:PP in addition to galU (20). However, in type 3
pneumococci the unencapsulated phenotype of the galU
mutants was somehow surprising since these bacteria con-
tain an active copy of cap3C that also codes for the same
enzymatic activity (16). Since Cap3C UDPG:PP activity is
not required for type 3 capsule formation and it cannot re-
place the activity lost in the galU mutants we conclude that,
at least under laboratory conditions, either Cap3C is poorly
translated or its enzymatic activity is very low. As the HasC
protein of S. pyogenes is also not needed for hyaluronate
biosynthesis (see above), it can be predicted that galU mu-
tants of GAS will be also unencapsulated. This observation
might be of remarkable clinical relevance since loss of cap-
sule is associated with a 100-fold reduction in virulence of
S. pyogenes (41).
The continuous dissemination of multiply resistant S.
pneumoniae clones throughout the world is the cause of
great concern, and much effort is currently dedicated to the
search for new antibacterial drugs (42, 43). The polysaccha-
ride capsule of pneumococcus is the main virulence factor
of this bacterium (3) and drugs inhibiting its biosynthesis
should potentially render S. pneumoniae virtually avirulent.
Unfortunately, the noticeable genetic variability found in
the genes responsible for the capsular polysaccharide bio-
synthesis has precluded until now the search for such drugs.
Remarkably, the galU gene has been found in all the pneu-
mococcal types tested so far (Fig. 3). The UDPG:PP,
which is directly involved in the synthesis of the capsular
polysaccharide in S. pneumoniae and other bacterial patho-
gens, might represent a suitable target for the search of in-
hibitors of such an important virulence factor. In this sense,
it should be emphasized that eukaryotic UDPG:PPs appear
to be completely unrelated to their prokaryotic counter-
parts (for review see reference 44). As depicted in Fig. 8,
the structural arrangement of the domains found in pro-
karyotic UDPG:PP is remarkably similar. In contrast, the
eukaryotic enzymes exhibit a completely different arrange-
ment as well as a different amino acid sequence. This inter-
esting feature suggests the possibility that putative inhibitors
of the bacterial enzymes would not be harmful for the host.
We thank J.L. García, and R. Muñoz for critical reading of the manuscript. The technical assistance of E.
Cano and M. Carrasco, as well as the artwork by V. Muñoz and A. Hurtado are greatly acknowledged.
This work was supported by grant PB96-0809 from the Dirección General de Investigación Científica y
Técnica and the Programa de Cooperación Científica con Iberoamérica from the Subdirección General de
Cooperación Internacional.
Address correspondence to Rubens López, Departamento de Microbiología Molecular, Centro de Investiga-
ciones Biológicas, Velázquez 144, 28006 Madrid, Spain. Phone: 34-91-561-1800; Fax: 34-91-562-7518;
E-mail: cibl220@fresno.csic.es
Received for publication 26 May 1998 and in revised form 9 September 1998.
References
1. Schuchat, A., K. Robinson, J.D. Wengetr, L.H. Harrison, M.
Farley, A.L. Reingold, L. Lefkowitz, and B.A. Perkins. 1997.
Bacterial meningitis in the United States in 1995. N. Engl. J.
Med. 337:970–976.
2. AlonsoDeVelasco, E., A.F. Verheul, J. Verhoef, and H.
Snippe. 1995. Streptococcus pneumoniae: virulence factors,
pathogenesis, and vaccines. Microbiol. Rev. 59:591–603.
3. Griffith, F. 1928. The significance of pneumococcal types. J.
Hyg. 27:113–159.
4. MacLeod, C.M., and M.R. Krauss. 1950. Relation of viru-
lence of pneumococcal strains for mice to the quantity of
capsular polysaccharide formed in vitro. J. Exp. Med. 92:1–9.
5. MacLeod, C.M., and M.R. Krauss. 1953. Control by factors
distinct from the S transforming principle of the amount of
capsular polysaccharide produced by type III pneumococci. J.
Exp. Med. 97:767–771.
6. Knecht, J.C., G. Schiffman, and R. Austrian. 1970. Some bi-
ological properties of pneumococcus type 37 and the chemis-
try of its capsular polysaccharide. J. Exp. Med. 132:475–487.
7. Kelly, T., J.P. Dillard, and J. Yother. 1994. Effect of genetic
switching of capsular type on virulence of Streptococcus pneu-
moniae. Infect. Immun. 62:1813–1819.
8. Henrichsen, J. 1995. Six newly recognized types of Streptococ-
cus pneumoniae. J. Clin. Microbiol. 33:2759–2762.
9. García, E., and R. López. 1997. Molecular biology of the
capsular genes of Streptococcus pneumoniae. FEMS (Fed. Eur.2055 Mollerach et al.
Microbiol. Soc.) Microbiol. Lett. 149:1–10.
10. Morona, J.K., R. Morona, and J.C. Paton. 1997. Molecular
and genetic characterization of the capsule biosynthesis locus
of Streptococcus pneumoniae type 19B. J. Bacteriol. 179:4953–
4958.
11. Kolkman, M.A., W. Wakarchuk, P.J. Nuijten, and B.A. van
der Zeijst. 1997. Capsular polysaccharide synthesis in Strepto-
coccus pneumoniae serotype 14: molecular analysis of the com-
plete cps locus and identification of genes encoding glycosyl-
transferases required for the biosynthesis of the tetrasaccharide
subunit. Mol. Microbiol. 26:197–208.
12. van Dam, J.E., A. Fleer, and H. Snippe. 1990. Immunogenic-
ity and immunochemistry of Streptococcus pneumoniae capsular
polysaccharides. Antonie van Leeuwenhoek. 58:1–47.
13. Mills, G.T., and E.E.B. Smith. 1965. Biosynthesis of capsular
polysaccharides in the pneumococcus. Bull. Soc. Chim. Biol.
47:1751–1765.
14. Frey, P.A. 1996. The Leloir pathway: a mechanistic impera-
tive for three enzymes to change the stereochemical configu-
ration of a single carbon in galactose. FASEB (Fed. Am. Soc.
Exp. Biol.) J. 10:461–470.
15. Sundarajan, T.A., A.M.C. Rapin, and H.M. Kalckar. 1962.
Biochemical observations on Escherichia coli mutants defective
in uridine diphosphoglucose. Proc. Natl. Acad. Sci. USA. 48:
2187–2193.
16. Arrecubieta, C., E. García, and R. López. 1995. Sequence
and transcriptional analysis of a DNA region involved in the
production of capsular polysaccharide in Streptococcus pneumo-
niae type 3. Gene (Amst.). 167:1–7.
17. Dillard, J.P., M.W. Vandersea, and J. Yother. 1995. Charac-
terization of the cassette containing genes for type 3 capsular
polysaccharide biosynthesis in Streptococcus pneumoniae. J. Exp.
Med. 181:973–983.
18. Lacks, S., and R.D. Hotchkiss. 1960. A study of the genetic
material determining an enzyme activity in Pneumococcus. Bio-
chim. Biophys. Acta. 39:508–517.
19. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular
Cloning. A Laboratory Manual. Cold Spring Harbor Labora-
tory, Cold Spring Harbor, NY. 6.22–6.31; A.12.
20. Muñoz, R., M. Mollerach, R. López, and E. García. 1997.
Molecular organization of the genes required for the synthesis
of type 1 capsular polysaccharide of Streptococcus pneumoniae:
formation of binary encapsulated pneumococci and identifi-
cation of cryptic dTDP-rhamnose biosynthesis genes. Mol.
Microbiol. 25:79–92.
21. Arrecubieta, C., R. López, and E. García. 1994. Molecular
characterization of cap3A, a gene from the operon required
for the synthesis of the capsule of Streptococcus pneumoniae type
3: sequencing of mutations responsible for the unencapsu-
lated phenotype and localization of the capsular cluster on the
pneumococcal chromosome. J. Bacteriol. 176:6375–6383.
22. Devereux, J., P. Haeberli, and O. Smithies. 1984. A compre-
hensive set of sequence analysis programs for the VAX. Nu-
cleic Acids Res. 12:387–395.
23. Laemmli, U.K. 1970. Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature. 227:
680–685.
24. Speicher, D.W. 1994. Methods and strategies for the se-
quence analysis of proteins on PVDF membranes. Methods.
6:262–273.
25. Ruoff, K.L. 1995. Streptococcus, In Manual of Clinical Micro-
biology, 6th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C.
Tenover, and R.H. Yolken, editors. American Society for
Microbiology, Washington, DC. 299–307.
26. Ravin, A.W. 1959. Reciprocal capsular transformation of
pneumococci.  J. Bacteriol. 77:296–309.
27. Arrecubieta, C., R. López, and E. García. 1996. Type 3–spe-
cific synthase of Streptococcus pneumoniae (Cap3B) directs type
3 polysaccharide biosynthesis in Escherichia coli and in pneu-
mococcal strains of different serotypes. J. Exp. Med. 184:
449–455.
28. Morbidoni, H.R., D. de Mendoza, and J.E. Cronan. 1995.
Synthesis of sn-glycerol 3-phosphate, a key precursor of
membrane lipids, in Bacillus subtilis. J. Bacteriol. 177:5899–
5905.
29. Crater, D.L., B.A. Dougherty, and I. van de Rijn. 1995. Mo-
lecular characterization of hasC from an operon required for
hyaluronic acid synthesis in group A streptococci. J. Biol.
Chem. 270:28676–28680.
30. Soldo, B., V. Lazarevic, P. Margot, and D. Karamata. 1993.
Sequencing and analysis of the divergon comprising gtaB, the
structural gene of UDP-glucose pyrophosphorylase of Bacillus
subtilis 168. J. Gen. Microbiol. 139:3185–3195.
31. Weissborn, A.C., Q. Liu, M.K. Rumley, and E.P. Kennedy.
1994. UTP:a-d-glucose-1-phosphate uridylyltransferase of
Escherichia coli: isolation and DNA sequence of the galU gene
and purification of the enzyme. J. Bacteriol. 176:2611–2618.
32. Marolda, C.L., and M.A. Valvano. 1996. The GalF protein of
Escherichia coli is not a UDP-glucose pyrophosphorylase but
interacts with the GalU protein possibly to regulate cellular
levels of UDP-glucose. Mol. Microbiol. 22:827–840.
33. Avery, O.T., C.M. MacLeod, and M. McCarty. 1944. Stud-
ies on the chemical nature of the substance inducing transfor-
mation of pneumococcal types. Induction of transformation
by a deoxyribonucleic acid fraction isolated from pneumo-
coccus type III. J. Exp. Med. 79:137–158.
34. Gasc, A.M., L. Kauc, P. Barraillé, M. Sicard, and S. Goodgal.
1991. Gene localization, size, and physical map of the chro-
mosome of Streptococcus pneumoniae. J. Bacteriol. 173:7361–
7367.
35. Crater, D.L., and I. van de Rijn. 1995. Hyaluronic acid syn-
thesis operon (has) expression in group A streptococci. J. Biol.
Chem. 270:18452–18458.
36. Dougherty, B.A., and I. van de Rijn. 1992. Molecular char-
acterization of a locus required for hyaluronic acid capsule
production in group A streptococci. J. Exp. Med. 175:1291–
1299.
37. DeAngelis, P.L., J. Papaconstantinou, and P.H. Weigel.
1993. Isolation of a Streptococcus pyogenes gene locus that di-
rects hyaluronan biosynthesis in acapsular mutants and in het-
erologous bacteria. J. Biol. Chem. 268:14568–14571.
38. Wandersman, C., and S. Létoffé. 1993. Involvement of li-
popolysaccharide in the secretion of Escherichia coli alpha-
haemolysin and Erwinia chrysanthemi proteases. Mol. Microbiol.
7:141–150.
39. Sandlin, R.C., K.A. Lampel, S.P. Keasler, M.B. Goldberg,
A.L. Stolzer, and A.T. Maurelli. 1995. Avirulence or rough
mutants of Shigella flexneri: requirement of O antigen for cor-
rect unipolar localization of IcsA in the bacterial outer mem-
brane. Infect. Immun. 63:229–237.
40. Chang, H.Y., J.H. Lee, W.L. Deng, T.F. Fu, and H.L. Peng.
1996. Virulence and outer membrane properties of a galU
mutant of Klebsiella pneumoniae CG43. Microb. Pathog. 20:
255–261.
41. Wessels, M.R., A.E. Moses, J.B. Goldberg, and T.J. DiCe-
sare. 1991. Hyaluronic acid capsule is a virulence factor for2056 Pneumococcal UDP-Glucose Pyrophosphorylase and Capsular Biosynthesis
mucoid group A streptococci. Proc. Natl. Acad. Sci. USA. 88:
8317–8321.
42. Tomasz, A. 1994. Multiple-antibiotic-resistant pathogenic
bacteria. A Report on the Rockefeller University Workshop.
N. Engl. J. Med. 330:1247–1251.
43. Lawler, A. 1995. Antibiotics that resist resistance. Science. 270:
724–727.
44. Flores-Díaz, M., A. Alape-Girón, B. Persson, P. Pollesello,
M. Moos, C. von Eichel-Streiber, M. Thelestam, and I.
Florin. 1997. Cellular UDP-glucose deficiency caused by a
single point mutation in the UDP-glucose pyrophosphorylase
gene. J. Biol. Chem. 272:23784–23791.
45. García, E., P. García, and R. López. 1993. Cloning and se-
quencing of a gene involved in the synthesis of the capsular
polysaccharide of Streptococcus pneumoniae type 3. Mol. Gen.
Genet. 239:188–195.
46. Liu, H.H., and A. Tomasz. 1985. Penicillin tolerance in mul-
tiply drug-resistant natural isolates of Streptococcus pneumoniae.
J. Infect. Dis. 152:365–372.
47. Hanahan, D. 1983. Studies on transformation of E. coli with
plasmids. J. Mol. Biol. 166:557–580.
48. Giæver, H.M., O.B. Styrvold, I. Kaasen, and A.R. Strøm.
1988. Biochemical and genetic characterization of osmoregu-
latory trehalose synthesis in Escherichia coli. J. Bacteriol. 170:
2841–2849.
49. Yanisch-Perron, C.J., J. Vieira, and J. Messing. 1985. Im-
proved M13 phage cloning vectors and host strains: nucle-
otide sequence of M13mp18 and pUC19 vectors. Gene
(Amst.). 33:103–119.
50. Corpet, F., J. Gonzy, and D. Kahn. 1998. The ProDom data-
base of protein domain families. Nucleic Acids Res. 26:323–326.